Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | Complete | |||
Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Xcopri | cenobamate | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Xeljanz | tofacitinib | Cancelled | ||||
Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete |